Skip to content
Peptigraph home

Melanotan II

Melanocortin agonist. Melanotan II is not FDA approved for any use.

Also called:MT2MT-II
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusOff FDA Category 2 (Apr 2026)Removed from FDA Category 2 on 15 Apr 2026. WADA status unclearFull legal history

Key facts

Class
Melanocortin agonist
Also called
MT2, MT-II
Vial sizes sold
10 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Unclear
Not named on the 2026 list
Everything on Melanotan II

Melanotan II guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Melanotan II: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
LibidoNot in our ledgerNot in our ledger2Human RCT evidence, 4 of 4International journal of impotence research 2000, PMID 11035391
EnergyNot in our ledgerNot in our ledger0No graded study for this goal
Muscle growthNot in our ledgerNot in our ledger0No graded study for this goal

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A cyclic alpha-MSH analogue that tans and has other effects

Melanotan II is a cyclic alpha-MSH analogue that is used unlicensed to promote skin pigmentation.[12]

The tanning claim rests on a small pilot study, which found tanning activity after just 5 low subcutaneous doses.[5]

Effects beyond skin colour

In a double-blind crossover study of men with erectile dysfunction, Melanotan II led to penile erection without sexual stimulation in 17 of 20 men.[6]

At the 0.03 mg/kg dose in the pilot study, one of two subjects had Grade II somnolence and fatigue.[5]

In rats, chronic infusion into the brain produced a severe but transient reduction in feeding. This is animal data.[13]

Case reports only, not frequencies

A case report describes melanoma in a young woman after a course of self-injected Melanotan II, who also had intense universal pigmentation.[12]

A case report describes systemic toxicity with rhabdomyolysis after Melanotan II injection.[14]

A forensic analysis of a vial labelled Melanotan II determined a purity of 30%.[15]

Regulatory path

Drugs@FDA has no Melanotan II product.[3]

FDA removed Melanotan II from category 2 after the nominations were withdrawn, and said it intends to consult its advisory committee before the end of February 2027.[4]

Common stacks

Melanotan II is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is Melanotan II FDA approved?

No. Melanotan II is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is MT2?

Short for Melanotan II, a cyclic peptide.[5]

What does MT2 do?

In a small pilot it darkened skin; a separate study in men with erectile dysfunction found it triggered erections.[5]

Is there a Melanotan nasal spray?

Only as a case report: one patient who used a nasal spray had an oral mucosal malignant melanoma, which does not prove cause.[16]

Is Melanotan II legal in the US?

Melanotan II is not an FDA-approved drug. It was removed from FDA's category 2 list because its nominations were withdrawn, and FDA intends to consult its compounding advisory committee before the end of February 2027 on adding it to the 503A bulks list. The legal page has the full status.[4]

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "Melanotan II" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4US compounding: Melanotan II was removed from FDA's 503A category 2 after the nominators withdrew; FDA announced a PCAC consultation before the end of February 2027.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  5. 5Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.Life sciences · 1996PMID 8637402Accessed 2 Oct 2026
  6. 6Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.International journal of impotence research · 2000PMID 11035391Accessed 2 Oct 2026
  7. 7PubMed search: "melanotan II"[tiab] OR "melanotan 2"[tiab] (198 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("melanotan II"[tiab] OR melanotan[tiab]) AND humans[mh] (82 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab] OR melanotan[ti]) AND (case[tiab] OR naevi[tiab] OR nevi[tiab] OR melanoma[tiab] OR adverse[tiab] OR priapism[tiab] OR tanning[tiab] OR sunless[tiab]) AND humans[mh] (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  12. 12Melanoma associated with the use of melanotan-II.Dermatology (Basel, Switzerland) · 2014PMID 24355990Accessed 2 Oct 2026
  13. 13The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat.Journal of neuroendocrinology · 2003PMID 12535159Accessed 2 Oct 2026
  14. 14Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.Clinical toxicology (Philadelphia, Pa.) · 2012PMID 23121206Accessed 2 Oct 2026
  15. 15Barbie drug identification: Not a child's play.Journal of forensic sciences · 2024PMID 39302005Accessed 2 Oct 2026
  16. 16Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?International journal of oral and maxillofacial surgery · 2025PMID 40210573Accessed 2 Oct 2026

Found an error? Report a correction.